Boston Scientific Corp. beat Wall Street’s second-quarter profit expectations but fell shy of analysts’ predictions on revenue. During an earnings call on 24 July, the company’s leadership detailed quarterly results and outlined expectations for the rest of the fiscal year.
CEO Michael Mahoney said he is “enthusiastic” about the company’s 2019 performance.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?